Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

Now Virtual

Providing high-quality

diabetes care

in a changing world

17 September 2020

Providing high-quality diabetes care
in a changing world

This year, the Northern Irish Conference of the PCDS is celebrating its 10th anniversary, and will be doing so in a new virtual format. Building on our heritage we will explore how we will be building a new future for clinical diabetes care in Northern Ireland. Among the topics that we will cover are adapting to COVID-19, how to run a remote clinic, new evidence in diets, and latest advice on managing mental health in the context of diabetes.

As always, you will be able to pick up best-practice tips and hear from the experts on a whole range of clinical issues that are central to high-quality diabetes care.

We very much hope to see you (virtually) there.

Northern Ireland Representatives on the PCDS Committee

Heather Bell, GP, Greenisland

Nigel Campbell, GP, Lisburn

Lesley Hamilton, Diabetes Network Manager and Specialist Dietitian

Why attend? This fast-paced, interactive conference combines latest clinical guidance, research, case studies and hot topics in diabetes, including lessons learned from COVID-19 and much more.

Ask the experts your burning questions through the LIVE Q&A at the end of each session

Log on anytime during the day from the comfort of your own home to view the sessions

Don’t worry if you miss something, all of the content will be available on-demand

Claim 5 CPD points for the full-day virtual conference

17 September 2020


09.00 - 09.10

Chair’s introduction

Nigel Campbell

09.10 - 09.40

COVID-19 Setting the scene – where are we now?

Hamish Courtney

15 minute break

09.55 - 10.25

Managing Cardiovascular risk in Type 2 Diabetes: Evidence into Primary Care Practice

Naresh Kanumilli (Speaker)
Vinesh Sobha (Chair)

15 minute break

10.40 - 11.10

How to set up a remote diabetes clinic and risk strategy

Heather Bell

15 minute break

11.25 - 12.05

‘In Practice’ masterclasses

Rotation 1

1.Foot assessment

Bronagh Monaghan

2. Diet

Lesley Hamilton

3. Mental Health

Mark Davies

4. FreeStyle Libre – Real world evidence – The expanding role of TIR and other CGM Metrics

Fraser Gibb

15 minute break

12.20 - 13.00

Rotation 2

1. Foot assessment

Bronagh Monaghan

2. Diet

Lesley Hamilton

3. Mental Health

Mark Davies

15 minute break

13.15 - 13.45

Diabetes Distilled

Kevin Fernando

15 minute break

14.00 - 14.30

CREDENCE Trial – A New Era in the Treatment of Diabetic Kidney Disease (DKD) in Type 2 Diabetes Mellitus (T2DM)

Anna Strzelecka

15 minute break

14.45 - 15.15

How to manage complex cases in diabetes

Su Down

15.15 - 15.25

Chair’s concluding remarks

Nigel Campbell

A full-day virtual conference

17 September 2020 from 9am

Including a LIVE Q&A after every session


Heather Bell, GP


Nigel Campbell

GP, Lisburn

Hamish Courtney

Consultant Diabetologist, Belfast

Mark Davies

Consultant Clinical Psychologist, Belfast

Su Down

Diabetes Nurse Consultant, Somerset

Kevin Fernando

GPwSI in Diabetes and Medical Education, North Berwick

Fraser Gibb

Consultant Endocrinologist and Honorary Senior Lecturer

Lesley Hamilton

Diabetes Network Manager, Western Trust

Naresh Kanumilli

Community Diabetes Consultant, MUFT Clinical Champion, Diabetes UK Clinical Network Lead for Diabetes, Greater Manchester

Bronagh Monaghan

Consultant Podiatrist in Diabetes, Belfast

Vinesh Sobha

GpwSI in Diabetes, Lancashire

Anna Strzelecka

SAS doctor in General Medicines & Endocrinology, Antrim




AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AstraZeneca operates in five different locations in the UK, where around 8,300 employees work in research and development, manufacturing, supply, sales and marketing. We supply 40 different medicines to the NHS. The UK is also an important location for AstraZeneca’s clinical trials; in 2018, there were 201 trials at 376 centres in the UK, involving over 7,000 patients. For more information, please visit


Napp Pharmaceuticals Limited

Napp Pharmaceuticals Limited is a UK healthcare company with a strong track record in bringing high-quality, innovative medicines to UK health professionals and their patients. We strive to offer new medicines and initiatives that support the NHS in delivering effective, high-quality, sustainable healthcare for the benefit of patients

Masterclass sponsor

Abbott’s Diabetes Care Division

Abbott’s diabetes care division is a global leader in glucose monitoring systems. We are dedicated to helping people manage their diabetes and achieve their best health outcomes with innovative technology, such as the FreeStyle Libre system, allowing patients to monitor their glucose with a quick and easy scan. For more information, such as how the FreeStyle Libre system and our digital health tools support healthcare professionals and their patients visit


Boehringer Ingelheim and Lilly Diabetes Alliance

In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance that centres on compounds representing several of the largest diabetes treatment classes. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributing to the alliance. The Alliance leverages the strengths of two of the world’s leading pharmaceutical companies to focus on patient needs. By joining forces, the companies demonstrate their commitment, not only to the care of people with diabetes, but also to investigating the potential to address areas of unmet medical need


AgaMatrix manufactures and supplies WaveSense JAZZ™ blood glucose meters, diabetes data management solutions and provides services and support to help you reduce the cost of diabetes care.

With uncompromising accuracy as our cornerstone, we strive to ensure the highest quality diabetes monitoring products and services are supplied at the lowest possible cost.

Find out about our innovative new device, JAZZ™ DoseCoach, the UK’s first evidence-based basal insulin only advisor with built-in blood glucose meter.  The device helps patients with type 2 diabetes optimise their once daily insulin glargine dose and is proven to reduce HbA1c.


BD Diabetes Care have been specialising in the design and manufacture of insulin needles and syringes for over 90 years. BD’s culture of innovation and continuous improvement has enhanced the patient experience to enable better diabetes therapy and outcomes. BD and Me™ and BD Injection technique training programmes for HCPs and patients, have been designed to provide information on correct injection technique to better manage diabetes for those injecting1.

>1.Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013 Oct;39(5):445-53. doi: 10.1016/j.diabet.2013.05.006. Epub 2013 Jul 22.

Boehringer Ingelheim in the UK

We are Boehringer Ingelheim – a different kind of pharmaceutical company. Family-owned. Purpose-led. Innovation-driven: We serve mankind by improving health for people and animals.

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Established in 1885, we have always been independent and family-owned, meaning we have the freedom to pursue our purpose – identifying health challenges of the future, and targeting areas of need where we can do the most good.

By working collaboratively, we accelerate the delivery of medical breakthroughs to transform the lives of patients now, and for generations to come.

In the UK we do this through scientific innovation – taking on the biggest challenges in medicine. We invest in sustainable healthcare – planning for the long term alongside the NHS and our partners in the veterinary world. We support digital transformation by partnering with innovators to drive healthcare improvements.

We are committed to tackling the challenge of climate change and are a certified carbon neutral organisation. We serve local and global communities through our social impact programme and we support social entrepreneurs who find healthcare solutions for the most vulnerable.

More information can be found at

PC-GB-102424 – Date of Preparation August 2020

Eli Lilly and Company Ltd

Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today, we are building upon this heritage by working to meet the diverse needs of people living with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit


Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time.

In the UK, where some of medicines have been helping patients for more than 50 years, we have a portfolio of over 500 products that include branded, generic, over the counter, antiretroviral and biosimilar medicines. Learn more at

Novo Nordisk

At Novo Nordisk, our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.

Novo Nordisk is a leading global healthcare company, founded in 1923 and our heritage has given us experience and capabilities that enable us to expand access to our medicines and work to prevent and ultimately cure disease by pioneering scientific breakthroughs.

Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products.

For more information visit


This conference was developed by the PCDS in conjunction with OmniaMed Communications. The sponsoring companies have had no input into the conference agenda, speaker selection or presentations, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible.

Providing high-quality

diabetes care

in a changing world

17 September 2020

Complete the registration form

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.